Nonsteroidal Selective Androgen Receptor Modulators and Selective Estrogen Receptor β Agonists Moderate Cognitive Deficits and Amyloid-β Levels in a Mouse Model of Alzheimer’s Disease
Sonia George,Géraldine H Petit,Gunnar K. Gouras,Patrik Brundin,Patrik Brundin,Roger Olsson,Roger Olsson +6 more
TLDR
It is found that ACP-105 given alone decreases anxiety-like behavior and when ACp-105 is administered in combination with AC-186, they increase the amyloid-β degrading enzymes neprilysin and insulin-degrading enzyme and decrease amyloids-β levels in the brain as well as improve cognition.Abstract:
Decreases of the sex steroids, testosterone and estrogen, are associated with increased risk of Alzheimer's disease. Testosterone and estrogen supplementation improves cognitive deficits in animal models of Alzheimer's disease. Sex hormones play a role in the regulation of amyloid-β via induction of the amyloid-β degrading enzymes neprilysin and insulin-degrading enzyme. To mimic the effect of dihydrotestosterone (DHT), we administered a selective androgen receptor agonist, ACP-105, alone and in combination with the selective estrogen receptor β (ERβ) agonist AC-186 to male gonadectomized triple transgenic mice. We assessed long-term spatial memory in the Morris water maze, spontaneous locomotion, and anxiety-like behavior in the open field and in the elevated plus maze. We found that ACP-105 given alone decreases anxiety-like behavior. Furthermore, when ACP-105 is administered in combination with AC-186, they increase the amyloid-β degrading enzymes neprilysin and insulin-degrading enzyme and decrease amyloid-β levels in the brain as well as improve cognition. Interestingly, the androgen receptor level in the brain was increased by chronic treatment with the same combination treatment, ACP-105 and AC-186, not seen with DHT or ACP-105 alone. Based on these results, the beneficial effect of the selective ERβ agonist as a potential therapeutic for Alzheimer's disease warrants further investigation.read more
Citations
More filters
Journal ArticleDOI
Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential.
TL;DR: This review provides an overview and update of compounds that have been recently reported as modulators of ERs, with a particular focus on their potential clinical applications.
Journal ArticleDOI
Sex and the development of Alzheimer's disease.
TL;DR: The combined effects of organizational and activational effects of sex steroids yield distinct sex differences in AD pathogenesis, a significant variable that must be more rigorously considered in future research.
Journal ArticleDOI
Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy.
TL;DR: Modifiable physiological mechanisms affecting the efficiency of Aβ clearance, including brain perfusion, obesity, diabetes, and sleep, will be outlined and new insights provide optimism for future therapeutic developments in AD research.
Journal ArticleDOI
Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer’s disease?
TL;DR: Development of substrate-selective IDE modulators could overcome possible adverse effects of IDE modulator associated with multiplicity of IDE targets, and help overcome pathophysiological link between type 2 diabetes and Alzheimer’s disease.
Journal ArticleDOI
Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
TL;DR: The review covers the evolution of research in this field over the last 25 years and proposes assigning drugs to 18 categories according to their mechanism(s) of action.
References
More filters
Journal ArticleDOI
Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles: Intracellular Aβ and Synaptic Dysfunction
Salvatore Oddo,Antonella Caccamo,Jason D. Shepherd,M. Paul Murphy,Todd E. Golde,Rakez Kayed,Raju Metherate,Mark P. Mattson,Yama Akbari,Frank M. LaFerla +9 more
TL;DR: The recapitulation of salient features of AD in these mice clarifies the relationships between Abeta, synaptic dysfunction, and tangles and provides a valuable model for evaluating potential AD therapeutics as the impact on both lesions can be assessed.
Journal ArticleDOI
The use of the elevated plus maze as an assay of anxiety-related behavior in rodents
Alicia A. Walf,Cheryl A. Frye +1 more
TL;DR: The elevated plus maze is a widely used behavioral assay for rodents and it has been validated to assess the anti-anxiety effects of pharmacological agents and steroid hormones, and to define brain regions and mechanisms underlying anxiety-related behavior.
Journal ArticleDOI
Estrogen Receptors: How Do They Signal and What Are Their Targets
Nina Heldring,Ashley C. W. Pike,Sandra Andersson,Jason Matthews,Guojun Cheng,Johan Hartman,Michel Tujague,Anders Ström,Eckardt Treuter,Margaret Warner,Jan-Åke Gustafsson +10 more
TL;DR: This review focuses on several of the interesting recent discoveries concerning estrogen receptors, on estrogen as a morphogen, and on the molecular mechanisms of anti-estrogen signaling.
Journal ArticleDOI
Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice
TL;DR: This study strongly implicates intraneuronal Abeta in the onset of cognitive dysfunction in the 3xTg-AD mice, and rescues the early cognitive deficits on a hippocampal-dependent task.
Journal ArticleDOI
The spectrum of behavioral changes in Alzheimer's disease
TL;DR: Agitation, dysphoria, apathy, and aberrant motor behavior were significantly correlated with cognitive impairment in patients with Alzheimer's disease compared with normal age-matched control subjects.